
|Articles|November 6, 2006
Accredo to distribute Elaprase
Advertisement
Accredo Health Group has been chosen as a specialty pharmacy provider for the new replacement enzyme idursulfase (Elaprase, Shire Genetic Therapies), used to treat Hunter syndrome, a rare, but life-threatening lysosomal storage disorder. Accredo will provide pharmacy management and prescription fulfillment services through its network of 39 pharmacies. Caremark Specialty Pharmacy will be the other provider to distribute the therapy.
To see more Hot off the Press news articles,
To go to the Drug Topics homepage,
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
GoodRx Offers Wegovy Weight-Loss Pill at Under $150 a Month
2
HHS Limits Vaccine Recommendations for Childhood Schedules
3
COVID-19 Vaccination Reduces Mortality Related to COPD
4
Bepirovirsen Meets Primary End Point for Functional Cure Rate of Hepatitis B
5










































































































































































































